CN Patent

CN111253394A — 选择性cdk4/6抑制剂的固态形式

Assigned to Pfizer Inc · Expires 2020-06-09 · 6y expired

What this patent protects

本发明涉及选择性CDK4/6抑制剂的固态形式，具体涉及具有改善的性质的式( 1 )乙酰基‑8‑环戊基‑5‑甲基‑2‑(5‑哌嗪‑1‑基‑吡啶‑2‑基氨基)‑8H‑吡啶并[2，3‑d]嘧啶‑7‑酮的结晶游离碱、包含该游离碱的药物组合物及剂型、以及制备及使用所述化合物、组合物及剂型用于治疗细胞增生疾病(诸如癌症)的方法。

USPTO Abstract

本发明涉及选择性CDK4/6抑制剂的固态形式，具体涉及具有改善的性质的式( 1 )乙酰基‑8‑环戊基‑5‑甲基‑2‑(5‑哌嗪‑1‑基‑吡啶‑2‑基氨基)‑8H‑吡啶并[2，3‑d]嘧啶‑7‑酮的结晶游离碱、包含该游离碱的药物组合物及剂型、以及制备及使用所述化合物、组合物及剂型用于治疗细胞增生疾病(诸如癌症)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111253394A
Jurisdiction
CN
Classification
—
Expires
2020-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.